ストックスクリーナーアプリを入手
712.12
0.23%
1.64
プレマーケット:
709.99
-2.13
-0.30%
前日終値:
$710.48
開ける：
$711
24時間の取引高:
320.38K
Relative Volume:
0.60
時価総額：
$56.86B
収益：
$4.17B
当期純損益:
$1.03B
株価収益率:
56.45
EPS:
12.6148
ネットキャッシュフロー:
$940.22M
1週間 パフォーマンス:
-0.04%
1か月 パフォーマンス:
+1.65%
6か月 パフォーマンス:
+35.21%
1年 パフォーマンス:
+68.38%
1日の値動き範囲:
$707.42
$715.11
1週間の範囲:
$701.49
$726.41
52週間の値動き範囲:
$356.14
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
名前
Idexx Laboratories Inc
セクター
電話
(207) 556-0300
住所
ONE IDEXX DRIVE, WESTBROOK, ME
IDXX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
712.12 | 56.73B | 4.17B | 1.03B | 940.22M | 12.61 |
|
TMO
Thermo Fisher Scientific Inc
|
624.65 | 233.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
239.89 | 168.08B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IQV
Iqvia Holdings Inc
|
241.28 | 41.10B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
144.83 | 41.37B | 6.95B | 1.30B | 1.15B | 4.5696 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-31 | アップグレード | Stifel | Hold → Buy |
| 2025-10-01 | 開始されました | UBS | Neutral |
| 2025-08-05 | 繰り返されました | BTIG Research | Buy |
| 2025-07-01 | 開始されました | Jefferies | Buy |
| 2024-12-02 | 開始されました | Leerink Partners | Outperform |
| 2024-07-25 | 開始されました | BTIG Research | Buy |
| 2024-01-30 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | 開始されました | Exane BNP Paribas | Outperform |
| 2023-12-04 | アップグレード | Cleveland Research | Neutral → Buy |
| 2023-08-02 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2022-07-21 | アップグレード | Goldman | Neutral → Buy |
| 2022-07-12 | 開始されました | Piper Sandler | Overweight |
| 2022-05-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-02-08 | 開始されました | Atlantic Equities | Overweight |
| 2021-11-18 | 開始されました | Morgan Stanley | Overweight |
| 2021-08-05 | 再開されました | Credit Suisse | Outperform |
| 2021-07-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-17 | 開始されました | Barclays | Overweight |
| 2019-09-09 | 開始されました | Goldman | Neutral |
| 2019-05-23 | 開始されました | Guggenheim | Buy |
| 2018-11-02 | 繰り返されました | BofA/Merrill | Buy |
| 2018-05-07 | 繰り返されました | Stifel | Buy |
| 2018-01-16 | 開始されました | Piper Jaffray | Overweight |
| 2017-08-23 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | アップグレード | CL King | Neutral → Buy |
| 2017-02-03 | ダウングレード | Feltl & Co. | Hold → Sell |
| 2016-09-29 | 再開されました | BofA/Merrill | Neutral |
| 2016-08-16 | 繰り返されました | Stifel | Buy |
| 2016-08-03 | アップグレード | Northcoast | Sell → Neutral |
| 2016-07-20 | 繰り返されました | Canaccord Genuity | Buy |
| 2016-04-19 | 繰り返されました | Canaccord Genuity | Buy |
| 2016-04-01 | 開始されました | CL King | Neutral |
| 2016-03-21 | 繰り返されました | Stifel | Buy |
| 2016-02-04 | 開始されました | Credit Suisse | Outperform |
| 2015-10-29 | 繰り返されました | Stifel | Buy |
| 2015-08-28 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | 繰り返されました | Stifel | Buy |
| 2015-07-23 | 繰り返されました | Canaccord Genuity | Buy |
すべてを表示
Idexx Laboratories Inc (IDXX) 最新ニュース
Ritholtz Wealth Management Acquires 7,773 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories, Inc. Launches ImageVue DR50 Plus - marketscreener.com
Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus - 01net
Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus (2026-01-15) - Seeking Alpha
IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs - Seeking Alpha
A Look At IDEXX Laboratories (IDXX) Valuation Following Planned CEO Succession Announcement - Sahm
Growth Recap: Whats the profit margin of IDEXX Laboratories IncPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Stifel Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - 富途牛牛
IDEXX Laboratories, Inc. $IDXX Stock Position Cut by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Michael Erickson to succeed Jay Mazelsky as IDEXX CEO in May 2026 - Investing.com Nigeria
How IDEXX’s Diagnostics-Focused CEO Transition At IDEXX Laboratories (IDXX) Has Changed Its Investment Story - Yahoo Finance
IDEXX Laboratories Names Michael Erickson CEO - citybiz
IDEXX Labs stock steady as Stifel notes CEO transition plan By Investing.com - Investing.com Australia
IDEXX Labs stock steady as Stifel notes CEO transition plan - Investing.com India
IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly - 富途牛牛
IDEXX Laboratories (IDXX) Announces CEO Transition - GuruFocus
IDEXX Laboratories, Inc. Announces Management Changes, Effective May 12, 2026 - marketscreener.com
IDEXX Laboratories (IDXX): From a Detractor to a Revivor - Finviz
IDEXX Laboratories (IDXX) Announces Leadership Transition - GuruFocus
IDEXX CEO to retire; insider named as successor - Mainebiz
IDEXX appoints insider Michael Erickson as new CEO - marketscreener.com
Idexx Laboratories announces planned CEO succession and transition - TipRanks
Idexx announces CEO succession - marketscreener.com
IDEXX Laboratories Announces CEO Transition - TradingView — Track All Markets
Dental EconomicsIDEXX Announces CEO Succession - FinancialContent
PKO Investment Management Joint Stock Co Grows Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Tema Etfs LLC Increases Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Unpacking a Healthcare Giant’s Potential Amidst a 7.38% Upside - DirectorsTalk Interviews
Sumitomo Mitsui DS Asset Management Company Ltd Increases Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Oregon Public Employees Retirement Fund Has $5.80 Million Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Nisa Investment Advisors LLC Sells 1,912 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
Is It Too Late To Consider Buying IDEXX Laboratories (IDXX) After A 71% One Year Rally - Yahoo Finance
Will IDEXX Laboratories Inc. stock outperform value stocksCushioning Options Review & walk-ready comfort choices - ulpravda.ru
IDEXX Laboratories Inc. (IDXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results - 01net
Fund Update: 152,368 IDEXX LABS (IDXX) shares added to CONGRESS ASSET MANAGEMENT CO portfolio - Quiver Quantitative
IDEXX Software Defect Blamed For At Least 40 Dog Deaths - Law360
What catalysts could drive IDEXX Laboratories Inc. stock higherTrail vs Road Selection & HOKA model picks for your routine - ulpravda.ru
Moran Wealth Management LLC Acquires New Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Is IDEXX (IDXX) Turning Diagnostics Momentum Into a More Durable Investment Narrative? - Sahm
Is IDEXX Laboratories Inc. (IX1) stock at risk of policy regulationMarket Performance Summary & Real-Time Chart Pattern Alerts - Улправда
Fundamentals Check: How IDEXX Laboratories Inc. stock trades before earningsAnalyst Downgrade & Real-Time Sentiment Analysis - ulpravda.ru
Is IDEXX Laboratories Inc. (IX1) stock undervalued historicallyJuly 2025 Rallies & Expert Approved Trade Ideas - Улправда
Will IDEXX Laboratories Inc. stock deliver consistent dividends2025 Market Trends & Weekly High Conviction Ideas - Улправда
Is IDEXX Laboratories Inc. stock attractive after correction2025 Earnings Surprises & AI Powered Market Entry Strategies - ulpravda.ru
Can IDEXX Laboratories Inc. (IX1) stock deliver double digit returnsQuarterly Risk Review & Capital Efficient Trading Techniques - ulpravda.ru
Veterinary Infectious Disease Diagnostics Market Forecast, 2025-2035, Featuring IDEXX Labs, Zoetis, Thermo Fisher Scientific, Virbac, bioMerieux and More - Yahoo Finance
Palo Alto, Capital One Financial, IDEXX Laboratories And Others: CNBC's 'Closing Trades' - Bitget
Smart Money: Is IDEXX Laboratories Inc. (IX1) stock at risk of policy regulationWeekly Trade Recap & Accurate Entry and Exit Point Alerts - Улправда
Palo Alto, Capital One Financial, IDEXX Laboratories And More: CNBC's 'Final Trades' - Benzinga
Idexx Laboratories Inc (IDXX) 財務データ
収益
当期純利益
現金流量
EPS
0.03%
0.48%
大文字化:
|
ボリューム (24 時間):